Trial Profile
A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined With ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms RACE IT
- 13 Sep 2022 Primary endpoint has been met. (Rate of patients with completed Treatment)
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 04 Jul 2022 Trial design presented at the 37th Congress of the European Association of Urology